RE: US & EU Melanoma Therapeutics Market Size 2025 (Scancell mentioned21 Feb 2026 21:47
There will be a tipping point where Institutional Investors start taking a position but that point will only happen once the path to the phase 3 is defined and financed.
Bermudashorts did point out that Scancell just needs sufficient funds to start the trial and set up the early clinical centres. As the size of the patient population increases more finance will be required.
So in reality we can borrow the capital, we can sell an asset, we can license out some more GlyMabs, we can fund raise enough to get started or sign a deal with a partner.
Our board will be discussing all avenues trying to figure out which is best for the whole company especially with Modi1 building up data, Modi2 in the wings and even more assets sat waiting for phase 1 starts ie: SC134.
I think it’s going to be the Insto’s or Big Pharma who will provide the catalyst to move the SP massively in one day.
I my opinion ……